Cookie Einstellungen
Diese Webseite verwendet ausschließlich notwendige Cookies, die für die Funktion erforderlich sind. Marketing- und Statistik-Cookies kommen nicht zum Einsatz. Weitere Informationen finden Sie in unserer Datenschutzerklärung.
 Notwendig   Details einblenden
      OK      
Bitte logge Dich ein, um diese Funktion zu nutzen!
      OK      
x
Impact News +++ Anleger aufgepasst: Hier entsteht ein neuer Rüstungswert made in Germany (Der Aktionaer) +++ DEUTZ Aktie +3,68%

SINOPHARM Aktie

 >SINOPHARM Aktienkurs 
1.756 EUR    -2.0%    (TradegateBSX)
Ask: 1.761 EUR / 5700 Stück
Bid: 1.736 EUR / 2920 Stück
Tagesumsatz: 6475 Stück
Realtime Kurs von 7:30 bis 22 Uhr!
SINOPHARM Aktie über LYNX handeln
>SINOPHARM Performance
1 Woche: -4,1%
1 Monat: -3,5%
3 Monate: -7,0%
6 Monate: -23,8%
1 Jahr: -17,7%
laufendes Jahr: -15,1%
>SINOPHARM Aktie
Name:  SINOPHARM GRP CO. H YC 1
Land:  China
Sektor:  Handel
ISIN/ Wkn:  CNE100000FN7 / A0N99U
Symbol/ Ticker:  X2S (Frankfurt)
Kürzel:  FRA:X2S, ETR:X2S, X2S:GR
Index:  -
Profil:  Sinopharm Group Co., Ltd. is a prominent healthcare conglomerate that plays a vital role in China's pharmaceutical industry. Specializing in the manufacturing, distribution, and retail of healthcare products, this state-owned enterprise is integral t..
>Volltext..
Marktkapitalisierung:  5646.36 Mio. EUR
Unternehmenswert:  16477.95 Mio. EUR
Umsatz:  68605.93 Mio. EUR
EBITDA:  2503.08 Mio. EUR
Nettogewinn:  853.67 Mio. EUR
Gewinn je Aktie:  0.27 EUR
Schulden:  12284.84 Mio. EUR
Liquide Mittel:  7219.7 Mio. EUR
Operativer Cashflow:  1464.03 Mio. EUR
Bargeldquote:  0.25
Umsatzwachstum:  -13.39%
Gewinnwachstum:  -10.65%
Dividende je Aktie:  0.09 EUR
Dividendenrendite:  4.76%
Dividendenschätzung:  4.8%
Div. Historie:  23.06.26 - 0.08861431€
16.06.25 - 0.081615165€
>weitere anzeigen...
Insiderhandel -
Suchwörter:  SINOPHARM
Letzte Datenerhebung:  25.08.26
>SINOPHARM Kennzahlen
Aktien/ Unternehmen:
Aktien: 1341.81 Mio. St.
Frei handelbar: 99.79%
Leerverk. Aktien: -
Rückkaufquote: -
Mitarbeiter: 94910
Umsatz/Mitarb.: 0.72 Mio. EUR
Analysten:
Analystenrating: Buy
Kursziel: 16.35%
Bewertung:
KGV: 6.84
KGV lG: 6.16
KUV: 0.08
KBV: 0.57
PEG-Ratio: 4.38
EV/EBITDA: 6.58
Rentabilität:
Bruttomarge: 6.94%
Gewinnmarge: 1.24%
Operative Marge: 2.9%
Managementeffizenz:
Gesamtkaprendite: 1.82%
Eigenkaprendite: 8.75%
>SINOPHARM Peer Group
Handel, Apotheken, Drogerien & Pharmavertrieb
 
25.08.26 - 08:30
SINOPHARM Falls 3.6% as Citi Cuts TP to HKD20.4 (AAStocks)
 
SINOPHARM (01099.HK) opened 2.02% lower today and hit a trough of HKD15.67. It is now trading at HKD15.75, down 3.55%, with turnover of 6.3919 million shares involving HKD101 million.Citi said in a report that SINOPHARM's first-half results missed expectations. Revenue was RMB282.8 billion, down 1.1% YoY, 2.3% below the broker's......
25.08.26 - 04:15
Research: Daiwa Cuts SINOPHARM TP to HKD17, 1H Results Slightly Miss Expectations (AAStocks)
 
Um den gesamten Artikel unter aastocks.com zu lesen, klicken Sie bitte auf die Überschrift...
17.08.26 - 17:00
SINOPHARM Subsidiary SINOPHARM ACCORD 1H26 Net Profit RMB606 million, Down 9% (AAStocks)
 
SINOPHARM (01099.HK) announced that its subsidiary SINOPHARM ACCORD (000028.SZ) reported results for the first half of the year. Total operating revenue was RMB36.266 billion, down 1.4% YoY. Net profit attributable to shareholders was RMB606 million, down 9%. EPS was RMB0.99. (de/d)~AASTOCKS Financial NewsWebsite: www.aastocks.c......
27.07.26 - 11:15
HBM HOLDINGS-B and SINOPHARM Enter Strategic Cooperation Covering Oncology and Immuno-Inflammatory Disease Areas (AAStocks)
 
HBM HOLDINGS-B (02142.HK) and SINOPHARM (01099.HK) signed a strategic cooperation agreement to establish an innovation consortium and collaborate in the research and development of innovative biologic drugs, with strategic focus covering oncology and immuno-inflammatory disease areas.The two parties will carry out R&D cooperatio......
27.07.26 - 11:06
Harbour BioMed and Sinopharm Enter Strategic Collaboration to Establish Innovation R&D Consortium (PR Newswire)
 
CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, July 27, 2026 /PRNewswire/ -- Harbour BioMed (HKEX: 02142), a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics in immunology, oncology and other areas, today announced that it......
09.07.26 - 10:00
Research: Daiwa Downgrades SINOPHARM to Hold, Cuts TP to HKD18 (AAStocks)
 
Daiwa said in a report that SINOPHARM (01099.HK)'s revenue has started to stabilize, but there is not yet a clear timetable for a rebound. Guidance for retail pharmacy revenue in 2026 indicates double-digit YoY growth. The rating was downgraded from "Outperform" to "Hold", while the target price was lowered from HKD21 to HKD18. ......
15.06.26 - 07:15
SINOPHARM Establishes Strategic Partnership with Pfizer, Inc. (AAStocks)
 
SINOPHARM (01099.HK) has recently formally established a strategic partnership with Pfizer, Inc. (PFE.US). The two parties will focus on the upgraded market promotion of Diflucan (fluconazole sodium chloride injection/fluconazole capsules), as well as in-depth cooperation on service enhancements for Pfizer's future new products.......
28.04.26 - 06:30
Research: Citi Slightly Cuts Sinopharm TP to HKD22.6; 1Q26 Results Largely In Line (AAStocks)
 
Citi published a research report stating that Sinopharm (01099.HK) recorded revenue of RMB140.8 billion in 1Q26, down 0.6% YoY and largely in line with the banks expectations. By segment, management indicated that pharmaceutical distribution revenue edged down YoY, while the YoY decline in medical device distribution narrowed, ......
28.04.26 - 06:15
Research: G Sachs Cuts Sinopharm TP to HKD19.07, Expects Gradual Revenue Recovery in Coming Quarters (AAStocks)
 
Um den gesamten Artikel unter aastocks.com zu lesen, klicken Sie bitte auf die Überschrift...
28.04.26 - 06:00
Research: CLSA Raises Sinopharm TP to HKD25, Maintains Outperform (AAStocks)
 
CLSA published a research report stating that Sinopharm (01099.HK)'s results last year were in line with expectations. Revenue in 4Q rose 1.1% YoY, while gross margin and operating profit margin narrowed by 0.62 ppts and 0.71 ppts, respectively. Benefiting from improved financial leverage and reduced finance costs, net profit st......
27.04.26 - 02:30
Sinopharm 1Q26 Net Profit RMB1.41 Billion, Down 3% YoY (AAStocks)
 
Sinopharm (01099.HK) announced its results for 1Q26 ended March, prepared in accordance with China Accounting Standards for Business Enterprises. Revenue amounted to RMB140.77 billion, down 0.6% YoY. Net profit was RMB1.41 billion, down 3% YoY. EPS was RMB0.45. (jl/w)~AASTOCKS Financial NewsWebsite: www.aastocks.comThis article ......
22.04.26 - 16:00
Sinopharm Subsidiary Sinopharm Co 1Q Net Profit RMB474M, Up 3.3% (AAStocks)
 
Sinopharm (01099.HK) announced that its subsidiary Sinopharm Co (600511.SH) released its first-quarter report. Revenue amounted to RMB13.555 billion, representing a YoY increase of 6.6%. Net profit attributable to shareholders reached RMB474 million, up 3.3%, with EPS at RMB0.6286. (de/d)~AASTOCKS Financial NewsWebsite: www.aast......
21.04.26 - 16:30
Sinopharm Group Subsidiary Sinopharm Consistent 1Q Net Profit RMB287M, Down 12.4% YoY (AAStocks)
 
Sinopharm Group (01099.HK) announced that its subsidiary Sinopharm Consistent (000028.SZ) released its first-quarter report. Total operating revenue was RMB17.823 billion, down 2.6% YoY. Net profit attributable to shareholders was RMB287 million, declining 12.4% YoY. EPS was RMB0.52. (de/d)~AASTOCKS Financial NewsWebsite: www.aa......
24.03.26 - 04:15
Research: Citi Keeps Buy on SINOPHARM but Slashes TP to HKD22.8 (AAStocks)
 
Um den gesamten Artikel unter aastocks.com zu lesen, klicken Sie bitte auf die Überschrift...
23.03.26 - 02:15
Results: SINOPHARM Annual NP Grows 1.5% to RMB7.155B; Final Div. RMB0.69 (AAStocks)
 
SINOPHARM (01099.HK) has announced its annual results for the period ended December 2025.The company's turnover declined by 1.6% YoY to RMB575.168 billion, while net profit amounted to RMB7.155 billion, up 1.5% YoY, with EPS at RMB2.29.A final dividend of RMB0.69 was declared, compared to the dividend of RMB0.68 in the same ......
19.03.26 - 14:48
Woori IO, an OSR Company, Signs NDA with Sinopharm for China Market and Global Multicenter Trials (PR Newswire)
 
BELLEVUE, Wash., March 19, 2026 /PRNewswire/ -- OSR Holdings, Inc. (NASDAQ: OSRH), a healthcare-focused holding company advancing innovative medical technologies, today announced that its subsidiary, Woori IO Co., Ltd. ("Woori IO"), has entered into a mutual non-disclosure agreement......
19.03.26 - 14:06
OSR Holdings, Inc.: Woori IO, an OSR Company, Signs NDA with Sinopharm to Explore China Commercial Opportunities (Accesswire)
 
BELLEVUE, WA / ACCESS Newswire / March 19, 2026 / OSR Holdings, Inc. (NASDAQ:OSRH), a healthcare-focused holding company advancing innovative medical technologies, today announced that its subsidia......
25.02.26 - 09:15
Full-day Takeaway: HSI Closes at 26,765, Up 175 pts; HSTI Closes at 5,260, Down 10 pts; HAIDILAO Up over 6%; HSBC HOLDINGS, TINGYI, SINOPHARM, TIME INTERCON, WANGUO GOLD GP Hit New Highs; Market Turnover Rises (AAStocks)
 
At close, HSI rose 175 pts or 0.7% to 26,765. HSTI dropped 10 pts or 0.2% to 5,260. HSCEI gained 26 pts or 0.3% to 9,034. Market turnover reached $236.77 billion.Active Heavyweights:PING AN (02318.HK) closed at $71.15, up 1.9%MEITUAN (03690.HK) closed at $82.7, up 1.6%TENCENT (00700.HK) closed at $522.5, up 0.5%XIAOMI (01810.HK)......
25.02.26 - 05:30
Midday Takeaway: HSI Closes Midday at 26,789, Up 199 pts; HSTI Closes Midday at 5,288, Up 17 pts; HAIDILAO Up over 5%; LI NING, SINOPHARM, CHINA RES MIXC, HENGAN INT'L, MTR CORPORATION Hit New Highs (AAStocks)
 
At midday close, HSI rose 199 pts or 0.8% to 26,789. HSTI rose 17 pts or 0.3% to 5,288. HSCEI gained 81 pts or 0.9% to 9,088.Active Heavyweights:MEITUAN (03690.HK) closed at $83.3, up 2.3%PING AN (02318.HK) closed at $71.4, up 2.3%TENCENT (00700.HK) closed at $526.5, up 1.3%BABA (09988.HK) closed at $149.3, up 0.9%XIAOMI (01810.......
24.02.26 - 09:15
Full-day Takeaway: HSI Down 491 pts; HSTI Down 114 pts; MEITUAN Down over 4%; PING AN Down over 4%; TENCENT Down over 3%; WH GROUP, HENDERSON LAND, CKI HOLDINGS, MTR CORPORATION, SINOPHARM Hit New Highs; Market Turnover Rises (AAStocks)
 
At close, HSI dropped 491 pts or 1.8% to 26,590. HSTI dropped 114 pts or 2.1% to 5,270. HSCEI fell 189 pts or 2.1% to 9,007. Market turnover reached $250.99 billion.Active Heavyweights:MEITUAN (03690.HK) closed at $81.4, down 4.2%PING AN (02318.HK) closed at $69.8, down 4.1%TENCENT (00700.HK) closed at $520, down 3.3%BABA (09988......
>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!
Zitat des Tages: Ästhetische Vorschriften existieren für mich nicht. Was auf mich wirkt, wirkt. - Theodor Fontane
>Aktienauflistung | >Aktienscreener | >Aktienkennzahlen | >Anleihen | >ETFs | >Fonds | >Branchen | >Länder | >Themen | >Redaktionen
Partner:    >TradegateBSX Börse | >Dukascopy | >TradingView | >Boersentreff- Partner

Börsentreff auf Facebook | Börsentreff auf X | Börsentreff auf Instagram

Copyright @ Boersentreff.de - Die Märkte im Blick!